Analytical Data
-
Gene name
5T4
- Application
-
Alternative Names
5T4；5T4；Trophoblast glycoProtein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13641
-
Expression Region
60-345aa
-
AA Sequence
DQCPALCECS EAARTVKCVN RNLTEVPTDL PAYVRNLFLT GNQLAVLPAG AFARRPPLAE LAALNLSGSR LDEVRAGAFE HLPSLRQLDL SHNPLADLSP FAFSGSNASV SAPSPLVELI LNHIVPPEDE RQNRSFEGMV VAALLAGRAL QGLRRLELAS NHFLYLPRDV LAQLPSLRHL DLSNNSLVSL TYVSFRNLTH LESLHLEDNA LKVLHNGTLA ELQGLPHIRV FLDNNPWVCD CHMADMVTWL KETEVVQGKD RLTCAYPEKM RNRVLLELNS ADLDCD
-
Molecular Weight
33 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the 5T4 recombinant protein has garnered significant interest due to its potential applications in cancer immunotherapy and diagnostics. 5T4 is a tumor-associated antigen primarily expressed in various malignancies, including renal cell carcinoma, lung cancer, and colorectal cancer, while being minimally present in normal tissues. This distinctive expression pattern makes 5T4 an attractive target for therapeutic strategies aimed at enhancing the immune system's ability to recognize and eliminate cancer cells. Researchers have been focusing on the engineering of 5T4 as a recombinant protein to be used in vaccine formulations or as an antigen in cancer immunotherapeutics. The development of 5T4-based therapies could lead to more effective treatment options with fewer side effects, as they may selectively target tumor cells expressing this antigen. Furthermore, the use of 5T4 in diagnostic assays may facilitate early detection and monitoring of cancer progression. Ongoing studies aim to elucidate its mechanisms of action, optimize production protocols, and evaluate its efficacy in clinical settings, thereby contributing to the advancement of precision medicine in oncology. Overall, the research surrounding the 5T4 recombinant protein represents a promising frontier in the fight against cancer, with the potential to improve patient outcomes through targeted therapies.
